| 2.01 0.03 (1.52%) | 09-17 15:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.48  |
1-year : | 2.9 |
| Resists | First : | 2.13 |
Second : | 2.48 |
| Pivot price | 1.64  |
|||
| Supports | First : | 1.69 |
Second : | 1.42 |
| MAs | MA(5) : | 1.82 |
MA(20) : | 1.65 |
| MA(100) : | 4.51 |
MA(250) : | 4.84 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 66.5 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 8.17 | Low : | 1.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SYRS ] has closed It is unclear right now based on current values. 62.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.1 - 2.11 | 2.11 - 2.12 |
| Low: | 1.77 - 1.78 | 1.78 - 1.78 |
| Close: | 1.97 - 1.98 | 1.98 - 1.99 |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Sat, 14 Sep 2024
Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - Simply Wall St
Fri, 13 Sep 2024
Insider Buying: President & CEO Conley Chee Acquires Shares of S - GuruFocus.com
Thu, 12 Sep 2024
Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance
Thu, 12 Sep 2024
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 1.414e+007 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 1,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.16e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 835 % |
| Return on Equity (ttm) | -51.1 % |
| Qtrly Rev. Growth | 4.15e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -248.99 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -111 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -13.17 |
| Dividend | 0 |
| Forward Dividend | 957530 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|